1. Marine n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Kidney Transplant Recipients: A Randomized, Placebo-Controlled Trial.
- Author
-
Jørgensen HS, Eide IA, Jenssen T, Åsberg A, Bollerslev J, Godang K, Hartmann A, Schmidt EB, and Svensson M
- Subjects
- Absorptiometry, Photon, Adult, Aged, Biomarkers blood, Calcium blood, Denmark, Docosahexaenoic Acids adverse effects, Double-Blind Method, Drug Combinations, Eicosapentaenoic Acid adverse effects, Female, Humans, Male, Middle Aged, Osteoporosis etiology, Osteoporosis physiopathology, Osteoporotic Fractures etiology, Osteoporotic Fractures physiopathology, Time Factors, Treatment Outcome, Bone Density drug effects, Dietary Supplements adverse effects, Docosahexaenoic Acids administration & dosage, Eicosapentaenoic Acid administration & dosage, Kidney Transplantation adverse effects, Osteoporosis prevention & control, Osteoporotic Fractures prevention & control
- Abstract
Kidney transplant recipients are at high risk of progressive bone loss and low-energy fractures in the years following transplantation. Marine n-3 polyunsaturated fatty acids (n-3 PUFA) supplementation may have beneficial effects on bone strength. The Omega-3 fatty acids in Renal Transplantation (ORENTRA) trial was an investigator initiated, randomized, placebo-controlled trial investigating the effects of marine n-3 PUFA supplementation after kidney transplantation. Effects of supplementation on bone mineral density (BMD) and calcium metabolism were pre-defined secondary endpoints. Adult kidney transplant recipients ( n = 132) were randomized to 2.6 g marine n-3 PUFA supplement or olive oil (control) from 8 to 52 weeks post-transplant. Dual energy X-ray absorptiometry was performed to assess changes in bone mineral density of hip, spine, and forearm, as well as trabecular bone score (TBS) of the lumbar spine. Student's t test was used to assess between-group differences. There were no differences in ΔBMD between the two groups (intervention vs. control) at lumbar spine (-0.020 ± 0.08 vs. -0.007 ± 0.07 g/cm², p = 0.34), total hip (0.001 ± 0.03 vs. -0.005 ± 0.04, p = 0.38), or other skeletal sites in the intention-to-treat analyses. There was no difference in the change in TBS score (0.001 ± 0.096 vs. 0.009 ± 0.102, p = 0.62). Finally, no effect on biochemical parameters of mineral metabolism was seen. Results were similar when analyzed per protocol. In conclusion, we found no significant effect of 44 weeks of supplementation with 2.6 g of marine n-3 PUFA on BMD in kidney transplant recipients.
- Published
- 2021
- Full Text
- View/download PDF